The Phase 3 Oral-lyn study was predominantly done in the US (plus like most also Europe, Russia and Ecuador since Generex had a collaboration there.) Dr J Guievera (sp) screwed up registration or something silly to the FDA on his site in Ecuador. So all subjects were disqualified from results. If you backed out the error on his end and from Anna with a limited formulation (way too many doses evidently) it actually showed promising signs of efficacy.

But regarding recruitment for an Ii-Key SARS Covid don’t believe that the sky is falling lol. We in the US will be no where near dosing 350 million people in the next few months. Or further out. And no projection says so. It’s a non issue. But of course Generex needs to move the ball down the field.